Table 1

Patient demographics and baseline characteristics, intent-to-treat population

FF 100 μg (N=1010)FF/VI 100/25 μg (N=1009)Total (N=2019)
Age, years42.3 (16.82)41.1 (17.10)41.7 (16.96)
Female sex, n (%)689 (68)661 (66)1350 (67)
Never smoked, n (%)868 (86)870 (86)1738 (86)
Former smoker, n (%)142 (14)139 (14)281 (14)
Number of exacerbations in last 12 months, n (%)
 01 (<1)01 (<1)
 1599 (59)553 (55)1152 (57)
 2229 (23)252 (25)481 (24)
 3100 (10)101 (10)201 (10)
 437 (4)57 (6)94 (5)
 >444 (4)46 (5)90 (4)
Duration of asthma, years15.8 (13.3)15.3 (12.8)15.5 (13.0)
Screening prebronchodilator FEV1, L2.10 (0.61)2.11 (0.61)2.11 (0.61)
Screening % predicted FEV169.0 (10.41)68.8 (10.62)68.9 (10.52)
Screening % reversibility FEV124.3 (12.10)24.4 (12.71)24.4 (12.41)
Screening absolute reversibility FEV1, mL500.0 (260.25)499.1 (265.44)499.6 (262.79)
Baseline ACQ-7 score2.154 (0.7324)2.169 (0.7514)
Percentage of patients using ICS or ICS/LABA on entry
 ICS only397 (39)402 (40)
 ICS/LABA613 (61)607 (60)
  • Values are mean (SD) unless otherwise stated.

  • ACQ, Asthma Control Questionnaire; FEV1, forced expiratory volume in 1 s; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; VI, vilanterol.